(E)-5-氯-2-(3-甲氧基-4-(4-甲基-1H-咪唑-1-基)亚苄基)-戊酸叔丁酯 | 1225232-42-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 中文名称: (E)-5-氯-2-(3-甲氧基-4-(4-甲基-1H-咪唑-1-基)亚苄基)-戊酸叔丁酯
• 英文名称: 1,1-Dimethylethyl 5-chloro-2-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylene]pentanoate
• 英文别名: tert-butyl 5-chloro-2-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]pentanoate
• CAS: 1225232-42-7
• 化学式: C₂₁H₂₇ClN₂O₃
• 分子量: 390.91
• InChiKey: JNFDBCRFDCPLDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  53.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-甲氧基-4-(4-甲基-1H-咪唑-1-基)苯甲醛 、 tert-butyl 5-chloro-2-(diethoxyphosphoryl)valerate 在 lithium hydroxide monohydrate 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 (E)-5-氯-2-(3-甲氧基-4-(4-甲基-1H-咪唑-1-基)亚苄基)-戊酸叔丁酯
  参考文献：
  名称：

  [EN] GAMMA SECRETASE MODULATORS
  [FR] MODULATEURS DE SÉCRÉTASE GAMMA

  摘要：

  在其许多实施例中，本发明提供了一类新型的杂环化合物，其化学式为：作为γ-分泌酶调节剂，制备这类化合物的方法，含有一种或多种这类化合物的药物组合物，制备含有一种或多种这类化合物的制剂的方法，以及使用这类化合物或药物组合物治疗、预防、抑制或改善与中枢神经系统相关的一种或多种疾病的方法。

  公开号：

  WO2010054067A1

文献信息

• Cinnamide compound
  申请人：Kimura Teiji

  公开号：US20060004013A1

  公开（公告）日：2006-01-05

  The present invention relates to a compound represented by Formula (I): (wherein Ar 1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar 2 represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X 1 represents (1) —C≡C— or (2) a double bond etc. which may be substituted; R 1 and R 2 represent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents. The object of the present invention is to find a therapeutic or preventive agent for diseases caused by Aβ. According to the present invention, a therapeutic or preventive agents for diseases caused by Aβ can be provided.

  本发明涉及一种由式（I）表示的化合物：（其中Ar1代表可以被1到3个取代基取代的咪唑基团；Ar2代表可以被1到3个取代基取代的吡啶基团、嘧啶基团或苯基；X1代表（1）-C≡C-或（2）可以被取代的双键等；R1和R2代表，例如，可以被取代的C1-6烷基或C3-8环烷基等）或其药理学上可接受的盐，并且用作药物剂。本发明的目的是寻找一种治疗或预防由Aβ引起的疾病的药剂。根据本发明，可以提供治疗或预防由Aβ引起的疾病的药剂。
• Cinnamide Compound
  申请人：Kimura Teiji

  公开号：US20080070902A1

  公开（公告）日：2008-03-20

  The present invention relates to a compound represented by Formula (I): (wherein Ar 1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar 2 represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X 1 represents (1) —C≡C— or (2) a double bond etc. which may be substituted; R 1 and R 2 represent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents.

  本发明涉及一种由公式(I)表示的化合物：（其中Ar1代表一个咪唑基，可以用1到3个取代基取代；Ar2代表一个吡啶基，嘧啶基或苯基，可以用1到3个取代基取代；X1代表（1）-C≡C-或（2）一个双键等，可以用取代基取代；R1和R2代表例如C1-6烷基或C3-8环烷基，可以用取代基取代）或其药学上可接受的盐，并用作制药剂。
• SALTS OF CYNNAMIDE COMPOUND OR SOLVATES THEREOF
  申请人：Kushida Ikuo

  公开号：US20090048448A1

  公开（公告）日：2009-02-19

  The invention provides crystals of dihydrochloride monohydrate of the compound of the following formula having an Aβ production inhibiting effect which crystals are characterized by exhibiting a diffraction peak at an angle of diffraction (2θ±0.2°) of 10.9° in powder X-ray diffractometry. Further, the invention also provides the compound in the form of various salts, crystal forms and amorphous forms which are suitable for the development of drugs.

  本发明提供了一种具有Aβ产生抑制作用的以下化合物的二盐酸一水合物晶体，该晶体的特征是在粉末X射线衍射测定中，以(2θ±0.2°)为衍射角度，出现10.9°的衍射峰。此外，本发明还提供了适用于药物开发的各种盐类、晶体形式和非晶态形式的该化合物。
• CINNAMIDE COMPOUND
  申请人：KIMURA Teiji

  公开号：US20090281310A1

  公开（公告）日：2009-11-12

  The present invention relates to a process for preparing a compound of formula (6a): wherein Ar 1 represents an imidazolyl group which may be substituted with 1 to 3 substituents shown below; Ar 2 represents a pyridinyl group, a pyrimidinyl group or a phenyl group which may be substituted with 1 to 3 substituents; and R 11 represents a group selected from certain substituents.

  本发明涉及一种制备式（6a）化合物的方法，其中Ar1代表一种咪唑基团，该基团可能被下列1至3个取代基取代；Ar2代表一种吡啶基团、嘧啶基团或苯基团，该基团可能被下列1至3个取代基取代；R11代表从某些取代基中选择的一种基团。
• COMPOUND
  申请人：KIMURA Teiji

  公开号：US20110086860A1

  公开（公告）日：2011-04-14

  A compound represented by Formula (I) is provided: wherein Ar 1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar 2 represents a phenyl group which may be substituted with 1 to 3 substituents; X 1 represents (1) —C≡C— or (2) a double bond etc., which may be substituted; R 1 and R 2 represent, for example, a C1-6 alkyl group which may be substituted, or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents.

  提供一种由式（I）表示的化合物： 其中Ar1代表一种咪唑基团，该基团可以被1到3个取代基取代；Ar2代表一种苯基团，该基团可以被1到3个取代基取代；X1代表（1）—C≡C—或（2）一个双键等，该双键可以被取代；R1和R2代表例如可以被取代的C1-6烷基或其药物学上可接受的盐，以及其作为制药剂的用途。